New advances in acute graft-versus-host disease prophylaxis

Transfusion Medicine

Volumn 13, Issue 6, 2003, Pages 387-397

  Davies, J K ^a   Lowdell, Mark W ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Anti viral immunity; Graft versus leukaemia; Immunotherapy; T cell depletion

Indexed keywords

CD25 IMMUNOTOXIN; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; GAMMA INTERFERON; IMMUNOTOXIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 11; INTERLEUKIN 2 MONOCLONAL ANTIBODY; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; T LYMPHOCYTE ANTIBODY; TACROLIMUS; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; CELL SELECTION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DEPLETION; DONOR; DRUG MECHANISM; DRUG SCREENING; GRAFT VERSUS HOST REACTION; HISTOCOMPATIBILITY; HLA TYPING; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LEUKEMIA; MORBIDITY; MORTALITY; NONHUMAN; REVIEW; T LYMPHOCYTE; VIRUS IMMUNITY;

ACUTE DISEASE; ANIMALS; ANTIGENS, CD; CLONAL ANERGY; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DRUG DESIGN; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MICE; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, HOMOLOGOUS;

EID: 0346118838     PISSN: 09587578     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-3148.2003.00466.x     Document Type: Review

References (62)

1. Alyea, E.P., Soiffer, R.J., Canning, C., Neuberg, D., Schlossman, R., Pickett, C.C., Collins, H., Wang, Y., Anderson, K.C. & Ritz, J. (1998) Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood, 91 (10), 3671-3680.
2. Ancin, I., Ferra, C., Gallardo, D., Peris, J., Berlanga, J., Gonzalez, J.R., Virgili, N. & Granena, A. (2001) Do corticosteroids add any benefit to standard GVHD prophylaxis in allogeneic BMT? Bone Marrow Transplantation, 28 (1), 39-45.
3. Andre-Schmutz, I., Le Deist, F., Hacein-Bey-Abina, S., Vitetta, E., Schindler, J., Chedeville, G., Vilmer, E., Fischer, A. & Cavazzana-Calvo, M. (2002) Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study. Lancet, 360 (9327), 130-137.
4. Antin, J.H., Lee, S.J., Neuberg, D., Alyea, E., Soiffer, R.J., Sonis, S. & Ferrara, J.L. (2002a) A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplantation, 29 (5), 373-377.
5. Antin, J.H., Weisdorf, D., Neuberg, D., Nicklow, R., Clouthier, S., Lee, S.J., Alyea, E., McGarigle, C., Blazar, B.R., Sonis, S., Soiffer, R.J. & Ferrara, J.L. (2002b) Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood, 100 (10), 3479-3482.
6. Ash, R.C., Casper, J.T., Chitambar, C.R., Hansen, R., Bunin, N., Truitt, R.L., Lawton, R., Murray, K., Hunter, J., Baxter-Lowe, L.A. et al. (1990) Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors. The New England Journal of Medicine, 322 (8), 485-494.
7. Atkinson, K., Farrelly, H., Cooley, M., O'Flaherty, E., Downs, K. & Biggs, J. (1987) Human marrow T cell dose correlates with severity of subsequent acute graft-versus-host disease. Bone Marrow Transplantation, 2 (1), 51-57.
8. Aversa, F., Tabilio, A., Velardi, A. & Martelli, M.F. (2001) Allogeneic transplantation across the HLA barriers. Review of Clinical and Experimental Hematology, 5 (2), 147-161.
9. Bacigalupo, A. (2002) Second EBMT Workshop on reduced intensity allogeneic hemopoietic stem cell transplants (RI-HSCT). Bone Marrow Transplantation, 29 (3), 191-195.
10. Billingham, R.E. (1966) The biology of graft-versus-host reactions. Harvey Lectures, 62, 21-78.
11. Blaise, D., Olive, D., Hirn, M., Viens, P., Lafage, M., Attal, M., Lawton, C., Murray, K., Hunter, J., Baxter-Lowe, L.A. et al. (1991) Prevention of acute GVHD by in vivo use of anti-interleukin-2 receptor monoclonal antibody (33B3.1): a feasibility trial in 15 patients. Bone Marrow Transplantation, 8 (2), 105-111.
12. Blaise, D., Olive, D., Michallet, M., Marit, G., Leblond, V. & Maraninchi, D. (1995) Impairment of leukaemia-free survival by addition of interleukin-2-receptor antibody to standard graft-versus-host prophylaxis. Lancet, 345 (8958), 1144-1146.
13. Blazar, B.R., Taylor, P.A., Linsley, P.S. & Vallera, D.A. (1994) In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blood, 83 (12), 3815-3825.
14. Brok, H.P., Vossen, J.M. & Heidt, P.J. (1998) IFN-gamma-mediated prevention of graft-versus-host disease: pharmacodynamic studies and influence on proliferative capacity of chimeric spleen cells. Bone Marrow Transplantation, 22 (10), 1005-1010.
15. Cavazzana-Calvo, M., Fromont, C., Le Deist, F., Lusardi, M., Coulombel, L., Derocq, J.M., Gerota, I., Griscelli, C. & Fischer, A. (1990) Specific elimination of alloreactive T cells by an anti-interleukin-2 receptor B chain-specific immunotoxin. Transplantation, 50 (1), 1-7.
16. Cavazzana-Calvo, M., Stephan, J.L., Samacki, S., Chevret, S., Fromont, C., de Coene, C., Le Deist, F., Guy-Grand, D. & Fischer, A. (1994) Attenuation of graft-versus-host disease and graft rejection by ex vivo immunotoxin elimination of alloreactive T cells in an H-2 haplotype disparate mouse combination. Blood, 83 (1), 288-298.
17. Chao, N.J. & Schlegel, P.G. (1995) Prevention and treatment of graft-versus-host disease. Annals of the New York Academy of Science, 770, 130-140.
18. Chao, N.J., Schmidt, G.M., Niland, J.C., Amylon, M.D., Dagis, A.C., Long, G.D., Nademanee, A.P., Negrin, R.S., O'Donnell, M.R., Parker, P.M. et al. (1993) Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. The New England Journal of Medicine, 329 (17), 1225-1230.
19. Chen, B.J., Cui, X., Liu, C. & Chao, N.J. (2002) Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process. Blood, 99 (9), 3083-3088.
20. Cooke, K.R., Gerbitz, A., Crawford, J.M., Teshima, T., Hill, G.R., Tesolin, A., Rossignol, D.P. & Ferrara, J.L. (2001) LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. The Journal of Clinical Investigation, 107 (12), 1581-1589.
21. Craston, R., Koh, M., Mc, D.A., Ray, N., Prentice, H.G. & Lowdell, M.W. (1997) Temporal dynamics of CD69 expression on lymphoid cells. Journal of Immunological Methods, 209 (1), 37-45.
22. Dickinson, A.M., Sviland, L., Hamilton, P.J., Usher, P., Taylor, P., Jackson, G., Dunn, J. & Proctor, S.J. (1994) Cytokine involvement in predicting clinical graft-versus-host disease in allogeneic bone marrow transplant recipients. Bone Marrow Transplantation, 13 (1), 65-70.
23. van Dijk, A.M., Kessler, F.L., Stadhouders-Keet, S.A., Verdonck, L.F., de Gast, G.C. & Otten, H.G. (1999) Selective depletion of major and minor histocompatibility antigen reactive T cells: towards prevention of acute graft-versus-host disease. British Journal of Haematology, 107 (1), 169-175.
24. Durie, F.H., Aruffo, A., Ledbetter, J., Crassi, K.M., Green, W.R., Fast, L.D. & Noelle, R.J. (1994) Antibody to the ligand of CD40, gp39, blocks the occurrence of the acute and chronic forms of graft-vs-host disease. Journal of Clinical Investigation, 94 (3), 1333-1338.
25. Fehse, B., Frerk, O., Goldmann, M., Bulduk, M. & Zander, A.R. (2000) Efficient depletion of alloreactive donor T lymphocytes based on expression of two activation-induced antigens (CD25 and CD69). British Journal of Haematology, 109 (3), 644-651.
26. Ferrant, A., Latinne, D., Bazin, H., Straetmans, N., Cornet, A., de la Parra, B. & Michaux, J.L. (1995) Prophylaxis of graft-versus-host disease in identical sibling donor bone marrow transplant by anti-IL-2 receptor monoclonal antibody LO-Tact-1. Bone Marrow Transplantation, 16 (4), 577-581.
27. Ferrara, J., Mauch, P., Murphy, G. & Burakoff, S.J. (1985) Bone marrow transplantation: the genetic and cellular basis of resistance to engraftment and acute graft-versus-host disease. Survey Immunological Research, 4 (4), 253-263.
28. Garderet, L., Snell, V., Przepiorka, D., Schenk, T., Lu, J.G., Marini, F. et al. (1999) Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations. Transplantation, 67 (1), 124-130.
29. de Gast, G.C., Gratama, J.W., Verdonck, L.F., van Heugten, J.G., Zwaan, F.E., Phillips, D.I. & Mudde, G.G. (1989) The influence of T cell depletion on recovery of T cell proliferation to herpesviruses and Candida after allogeneic bone marrow transplantation. Transplantation, 48 (1), 111-115.
30. Godthelp, B.C., van Tol, M.J., Vossen, J.M. & van Den Elsen, P.J. (1999) T-Cell immune reconstitution in pediatric leukemia patients after allogeneic bone marrow transplantation with T-cell-depleted or unmanipulated grafts: evaluation of overall and antigen-specific T-cell repertoires. Blood, 94 (12), 4358-4369.
31. Guinan, E.C., Boussiotis, V.A., Neuberg, D., Brennan, L.L., Hirano, N., Nadler, L.M. & Gribben, J.G. (1999) Transplantation of anergic histoincompatible bone marrow allografts. The New England Journal of Medicine, 340 (22), 1704-1714.
32. Harris, D.T., Sakiestewa, D., Lyons, C., Kreitman, R.J. & Pastan, I. (1999) Prevention of graft-versus-host disease (GVHD) by elimination of recipient-reactive donor T cells with recombinant toxins that target the interleukin 2 (IL-2) receptor. Bone Marrow Transplantation, 23 (2), 137-144.
33. Hartwig, U.F., Robbers, M., Wickenhauser, C. & Huber, C. (2002) Murine acute graft-versus-host disease can be prevented by depletion of alloreactive T lymphocytes using activation-induced cell death. Blood, 99 (8), 3041-3049.
34. Hattori, K., Hirano, T., Miyajima, H., Yamakawa, N., Tateno, M., Oshimi, K., Kayagaki, N., Yagita, H. & Okumura, K. (1998) Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies. Blood, 91 (11), 4051-4055.
35. Helene, M., Lake-Bullock, V., Bryson, J.S., Jennings, C.D. & Kaplan, A.M. (1997) Inhibition of graft-versus-host disease. Use of a T cell-controlled suicide gene. Journal of Immunology, 158 (11), 5079-5082.
36. Hill, G.R., Cooke, K.R., Teshima, T., Crawford, J.M., Keith, J.C. Jr., Brinson, Y.S., Bungard, D. & Ferrara, J.L. (1998) Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. Journal of Clinical Investigation, 102 (1), 115-123.
37. Holler, E., Kolb, H.J., Mittermuller, J., Kaul, M., Ledderose, G., Duell, T., Seeber, B., Schleuning, M., Hintermeier-Knabe, R., Ertl, B. et al. (1995) Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F). Blood, 86 (3), 890-899.
38. Horowitz, M.M., Gale, R.P., Sondel, P.M., Goldman, J.M., Kersey, J., Kolb, H.J., Rimm, A.A., Ringden, O., Rozman, C., Speck, B. et al. (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood, 75 (3), 555-562.
39. Koh, M.B., Prentice, H.G., Corbo, M., Morgan, M., Cotter, F.E. & Lowdell, M.W. (2002) Alloantigen-specific T-cell depletion in a major histocompatibility complex fully mismatched murine model provides effective graft-versus-host disease prophylaxis in the presence of lymphoid engraftment. British Journal of Haematology, 118 (1), 108-116.
40. Koh, M.B., Prentice, H.G. & Lowdell, M.W. (1999) Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis. Bone Marrow Transplantation, 23 (10), 1071-1079.
41. Lampert, I.A., Moore, R.H., Huby, R. & Cohen, J. (1988) Observations on the role of endotoxin in graft-versus-host disease. Progress in Clinical Biological Research, 272, 351-359.
42. Levine, J.E., Uberti, J.P., Ayash, L., Reynolds, C., Ferrara, J.L., Silver, S.M., Braun, T., Yanki, G., Hutchinson, R. & Ratanatharathom, V. (2003) Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy. Biology of Blood and Marrow Transplantation, 9 (3), 189-197.
43. Lowdell, M.W., Craston, R., Ray, N., Koh, M., Galatowicz, G. & Prentice, H.G. (1998) The effect of T cell depletion with Campath-1M on immune reconstitution after chemotherapy and allogeneic bone marrow transplant as treatment for leukaemia. Bone Marrow Transplantation, 21 (7), 679-686.
44. Mavroudis, D.A., Dermime, S., Molldrem, J., Jiang, Y.Z., Raptis, A., van Rhee, F., Hensel, N., Fellowes, V., Eliopoulos, G. & Barrett, A.J. (1998) Specific depletion of alloreactive T cells in HLA-identical siblings: a method for separating graft-versus-host and graft-versus-leukaemia reactions. British Journal of Haematology, 101 (3), 565-570.
45. Mavroudis, D.A., Jiang, Y.Z., Hensel, N., Lewalle, P., Couriel, D., Kreitman, R.J., Pastan, I. & Barrett, A.J. (1996) Specific depletion of alloreactivity against haplotype mismatched related individuals by a recombinant immunotoxin: a new approach to graft-versus-host disease prophylaxis in haploidentical bone marrow transplantation. Bone Marrow Transplantation, 17 (5), 793-799.
46. Morris, E.C., Rebello, P., Thomson, K.J., Peggs, K.S., Kyriakou, C., Goldstone, A.H., Mckinnon, S. & Hale, G. (2003) Pharmacokinetics of alemtuzumab (CAMPATH-1H) used for in vivo and in vitro T-cell depletion in allogeneic transplants: relevance for early adoptive immunotherapy and infectious complications. Blood, 102 (1), 404-406.
47. + cells for prevention of graft-versus-host disease after bone marrow transplantation. A randomized controlled trial. Transplantation, 57 (1), 82-87.
48. Panoskaltsis-Mortari, A., Lacey, D.L., Vallera, D.A. & Blazar, B.R. (1998) Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice. Blood, 92 (10), 3960-3967.
49. Prentice, H.G., Blacklock, H.A., Janossy, G., Bradstock, K.F., Skeggs, D., Goldstein, G. & Hoffbrand, A.V. (1982) Use of anti-T-cell monoclonal antibody OKT3 to prevent acute graft-versus-host disease in allogeneic bone-marrow transplantation for acute leukaemia. Lancet, 1 (8274), 700-703.
50. Prentice, H.G., Blacklock, H.A., Janossy, G., Gilmore, M.J., Price-Jones, L., Tidman, N., Trejdosiewicz, L.K., Skeggs, D.B., Panjwani, D., Ball, S. et al. (1984) Depletion of T lymphocytes in donor marrow prevents significant graft-versus-host disease in matched allogeneic leukaemic marrow transplant recipients. Lancet, 1 (8375), 472-476.
51. Ratanatharathorn, V., Ferrara, J., Raymond, H., Braun, T. & Ayash, L. (2003) A phase I/II study of recombinant human keratinoctye growth factor in patients with high risk haematologic malignancies undergoing mismatched related or unrelated donor transplant. Biology of Blood and Marrow Transplantation, 9, 67.
52. Reisner, Y., Kapoor, N., Kirkpatrick, D., Pollack, M.S., DuPont, B., Good, R.A. & O'Reilly, R.J. (1981) Transplantation for acute leukaemia with HLA-A and B non-identical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells. Lancet, 2 (8242), 327-331.
53. Riddell, S.R., Elliott, M., Lewinsohn, D.A., Gilbert, M.J., Wilson, L., Manley, S.A., Lupton, S.D., Overell, R.W., Reynolds, T.C., Corey, L. & Greenberg, P.D. (1996) T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nature Medicine, 2 (2), 216-223.
54. Roux, E., Helg, C., Dumont-Girard, F., Chapuis, B., Jeannet, M. & Roosnek, E. (1996) Analysis of T-cell repopulation after allogeneic bone marrow transplantation: significant differences between recipients of T-cell depleted and unmanipulated grafts. Blood, 87 (9), 3984-3992.
55. + T cells toward Th2 responses. Journal of Leukocyte Biology, 68 (5), 633-640.
56. Soiffer, R.J., Fairclough, D., Robertson, M., Alyea, E., Anderson, K., Freedman, A., Bartlett-Pandite, L., Fisher, D., Schlossman, R.L., Stone, R., Murray, C., Freeman, A., Marcus, K., Mauch, P., Nadler, L. & Ritz, J. (1997) CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission. Blood, 89 (8), 3039-3047.
57. Solomon, S.R., Tran, T., Carter, C.S., Donnelly, S., Hensel, N., Schindler, J., Bahceci, E., Ghetie, V., Michalek, J., Mavroudis, D., Read, E.J. & Vitetta, E.S. & Barrett, A.J. (2002) Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: a strategy for GvHD prophylaxis in allogeneic PBSC transplantation. Cytotherapy, 4 (5), 395-406.
58. Taylor, P.A., Lees, C.J. & Blazar, B.R. (2002) The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood, 99 (10), 3493-3499.
59. Thomis, D.C., Marktel, S., Bonini, C., Traversari, C., Gilman, M., Bordignon, C. & Clackson, T. (2001) A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood, 97 (5), 1249-1257.
60. Tsukada, N., Akiba, H., Kobata, T., Aizawa, Y., Yagita, H. & Okumura, K. (2000) Blockade of CD134 (OX40)-CD134L interaction ameliorates lethal acute graft-versus-host disease in a murine model of allogeneic bone marrow transplantation. Blood, 95 (7), 2434-2439.
61. Yabe, H., Yabe, M., Mitsuda, R., Hoshi, N., Ozaki, K., Ishimaru, Y., Katsuta, M., Kim, R., Matsuda, M., Kato, S. et al. (1988) Clinical study of gut decontamination in bone marrow transplantation. Kansenshogaku Zasshi, 62 (6), 527-533.
62. Ziegler, S.F., Ramsdell, F., Hjerrild, K.A., Armitage, R.J., Grabstein, K. H., Hennen, K.B., Farrah, T., Fanslow, W.C., Shevach, E.M. & Alderson, M.R. (1993) Molecular characterization of the early activation antigen CD69: a type II membrane glycoprotein related to a family of natural killer cell activation antigens. European Journal of Immunology, 23 (7), 1643-1648.